Everest Medicines' Nefecon® (Budesonide Delayed-Release Capsules) has been approved by Singapore's Health Sciences Authority (HSA) for the treatment of adult patients with primary IgA nephropathy who are at risk of disease progression. Nefecon® (Budesonide Delayed-Release Capsules) is currently the first and only causative treatment for IgA nephropathy to have received full approval from the U.S. Food and Drug Administration (FDA).
Global study results demonstrated that, compared with placebo, Nefecon® (Budesonide Delayed-Release Capsules) not only achieves a sustained reduction in proteinuria but also lowers the risk of microscopic hematuria. More importantly, it delivers a clinically relevant and statistically significant therapeutic benefit in estimated glomerular filtration rate (eGFR) (p<0.0001), reducing the rate of renal function decline by 50%. It is projected to delay the progression of the disease to dialysis or kidney transplantation by 12.8 years.
As the only causative treatment for IgA nephropathy, Nefecon® (Budesonide Delayed-Release Capsules) has yielded favorable efficacy and safety data in the phase 3 clinical trial NefIgArd.
The complete 2-year data from the NefIgArd trial has further analyzed potential differences in treatment responses to Nefecon® (Budesonide Delayed-Release Capsules) between Asian patients (n=83) and Caucasian patients (n=275). The results indicated that, compared with placebo, a 9-month treatment with Nefecon® (Budesonide Delayed-Release Capsules) consistently and significantly slows down the decline in eGFR, preserves renal function, and brings about sustained reduction in proteinuria as well as lower risk of microscopic hematuria, in both Asian and Caucasian populations.
As the world's only causative therapeutic agent for IgA nephropathy, Nefecon® (Budesonide Delayed-Release Capsules) is an intestinal-targeted mucosal immune modulator. It reduces renal function decline by 50% in the general population and by up to 66% in the Chinese population, and is projected to delay the progression of the disease to dialysis or kidney transplantation by 12.8 years. Budesonide is a glucocorticoid with potent glucocorticoid activity and weak mineralocorticoid activity, with a first-pass metabolism rate of 90%, conferring a favorable safety profile.












